[go: up one dir, main page]

WO2008090209A3 - Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders - Google Patents

Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders Download PDF

Info

Publication number
WO2008090209A3
WO2008090209A3 PCT/EP2008/050850 EP2008050850W WO2008090209A3 WO 2008090209 A3 WO2008090209 A3 WO 2008090209A3 EP 2008050850 W EP2008050850 W EP 2008050850W WO 2008090209 A3 WO2008090209 A3 WO 2008090209A3
Authority
WO
WIPO (PCT)
Prior art keywords
glucopyranosyloxy
preventing
neurodegenerative disorders
pyrazoles
treating neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/050850
Other languages
French (fr)
Other versions
WO2008090209A2 (en
Inventor
Marion Wienrich
Juergen Reess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008090209(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of WO2008090209A2 publication Critical patent/WO2008090209A2/en
Publication of WO2008090209A3 publication Critical patent/WO2008090209A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of a glucopyranosyloxy-pyrazole as defined in claim 1 for the manufacture of a medicament for treating, preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof.
PCT/EP2008/050850 2007-01-26 2008-01-25 Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders Ceased WO2008090209A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101213 2007-01-26
EP07101213.2 2007-01-26

Publications (2)

Publication Number Publication Date
WO2008090209A2 WO2008090209A2 (en) 2008-07-31
WO2008090209A3 true WO2008090209A3 (en) 2008-10-02

Family

ID=39315016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/050850 Ceased WO2008090209A2 (en) 2007-01-26 2008-01-25 Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders

Country Status (4)

Country Link
AR (1) AR065034A1 (en)
CL (1) CL2008000223A1 (en)
TW (1) TW200843785A (en)
WO (1) WO2008090209A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020737A1 (en) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
WO2005021566A2 (en) * 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy- pirazoles, drugs containing said compounds the use and production method thereof
WO2006058597A1 (en) * 2004-12-03 2006-06-08 Merck Patent Gmbh Tetrahydropyrane derivatives for use as antidiabetics
WO2006062224A1 (en) * 2004-12-07 2006-06-15 Takeda Pharmaceutical Company Limited Carboxamide derivative
WO2006127842A2 (en) * 2005-05-23 2006-11-30 The Regents Of The University Of California Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease
WO2007014895A2 (en) * 2005-07-28 2007-02-08 Boehringer Ingelheim International Gmbh Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020737A1 (en) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
WO2005021566A2 (en) * 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy- pirazoles, drugs containing said compounds the use and production method thereof
WO2006058597A1 (en) * 2004-12-03 2006-06-08 Merck Patent Gmbh Tetrahydropyrane derivatives for use as antidiabetics
WO2006062224A1 (en) * 2004-12-07 2006-06-15 Takeda Pharmaceutical Company Limited Carboxamide derivative
WO2006127842A2 (en) * 2005-05-23 2006-11-30 The Regents Of The University Of California Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease
WO2007014895A2 (en) * 2005-07-28 2007-02-08 Boehringer Ingelheim International Gmbh Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200645, Derwent World Patents Index; AN 2006-445878, XP002487051 *

Also Published As

Publication number Publication date
WO2008090209A2 (en) 2008-07-31
AR065034A1 (en) 2009-05-13
CL2008000223A1 (en) 2008-05-23
TW200843785A (en) 2008-11-16

Similar Documents

Publication Publication Date Title
WO2008090209A3 (en) Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders
UA108198C2 (en) Substituted 2-acetamido-5-aryl-l, 2,4-triazolones and their use
JO2756B1 (en) 4T 4-(4- Cyano-2-thioaryl)dihydropyrimidinones and use thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
WO2008104306A3 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2007127263A3 (en) Therapeutic uses of urolithins
WO2008137633A3 (en) Methods of modulating cellular homeostatic pathways and cellular survival
IN2015DN00502A (en)
WO2008061720A3 (en) Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2008079993A3 (en) Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2008052139A3 (en) Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2009141541A3 (en) Use of kif13a and ap-1 inhibitors for inhibiting melanogenesis
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2009007532A3 (en) Use of a haemoglobin for the preparation of dressings and resulting dressings
EP2048141A4 (en) Optical pure dihydropyrimidine compounds, their uses in the manufacture of a medicamnent for the treatment or the prevention of virosis diseases
WO2007144057A3 (en) Antimicrobial carbon
MY150931A (en) Substituted oxazolidinones and their use
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2009123486A8 (en) Use of compounds in the treatment of tau-induced cytotoxicities
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701663

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08701663

Country of ref document: EP

Kind code of ref document: A2